Sung H. Lee's most recent trade in Tango Therapeutics Inc was a trade of 60,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics Inc | Sung H. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Sung H. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 10,000 | 10,000 | - | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,152 | 70,069 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2025 | 2,152 | 72,221 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.72 per share. | 22 Dec 2025 | 805 | 71,416 (0%) | 0% | 62.7 | 50,490 | Common Stock |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.02 per share. | 03 Dec 2025 | 1,560 | 67,917 (0%) | 0% | 65.0 | 101,431 | Common Stock |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.21 per share. | 02 Jun 2025 | 4,965 | 69,477 (0%) | 0% | 31.2 | 154,958 | Common Stock |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 41,326 | 41,326 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 32,687 | 74,442 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 9,016 | 9,016 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,304 | 41,755 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,303 | 38,987 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.51 per share. | 03 Dec 2024 | 1,536 | 37,451 (0%) | 0% | 51.5 | 79,119 | Common Stock |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 53,417 | 53,417 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 34,684 | 34,684 (0%) | 0% | 0 | Common Stock | |
| Vir biotech Inc | Sung H. Lee | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.89 per share. | 27 Mar 2024 | 6,008 | 100,492 (0%) | 0% | 9.9 | 59,404 | Common Stock |
| Vir biotech Inc | H. Sung Lee | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Lee H. Sung | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 40,000 | 106,500 (0%) | 0% | 0 | Common Stock | |
| Vir biotech Inc | Sung H. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 133,000 | 133,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Sung H. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 66,500 | 66,500 (0%) | 0% | 0 | Common Stock |